PureCycle Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter earnings release. PureCycle is an early-commercial-stage company developing licensed solvent-based purification technology to recycle polypropylene into ultra-pure recycled (UPR) resin.
Business context and operating progress
- The Ironton, Ohio facility began commissioning in April 2023, achieved mechanical completion, and produced pellets; however, output remained intermittent and sales were immaterial. The facility has expected annual capacity of approximately 107 million pounds at full operation.
- Management expected Ironton to be fully operational later in 2024. It cited mechanical challenges involving contaminant removal and continuous pelletizing, which delayed sustained production.
- Augusta, Georgia is planned as the first multi-line facility. The company had invested approximately $84.9 million in pre-construction engineering and long-lead equipment by year-end. Financing uncertainty was affecting its construction timeline.
- The company reported more than 20-year offtake and feedstock agreements, but these do not assure production, customer acceptance, or revenue at planned levels. FDA clearances cited apply to specified feedstock sources and conditions of use; additional submissions and testing were planned.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | Immaterial UPR resin sales; no clear dollar value provided | Not clearly stated in the supplied filing text |
| Operating costs and expenses | $113.9 million | $81.3 million |
| Operating loss | $113.9 million, as no material revenue was reported | Not separately stated in the summary data |
| Net loss | $101.7 million | $84.7 million |
| Net loss per share, basic | $0.62 | $0.54 |
| Net cash used in operating activities | $94.9 million | $65.5 million |
| Net cash used in investing activities | $102.1 million | $218.4 million |
| Net cash provided by financing activities | $272.0 million | $247.5 million |
| Available unrestricted liquidity at year-end | $121.6 million | $107.9 million |
| Restricted cash at year-end | $229.1 million | $163.6 million |
| Working capital at year-end | $107.0 million | $197.9 million |
| Total assets / stockholders’ equity at year-end | $1,039.4 million / $420.2 million | $861.3 million / $510.9 million |
Debt: Balance-sheet carrying debt, including the related-party note, was approximately $516.6 million at year-end. The filing also presents approximately $564.2 million of gross bonds and notes before discounts and issuance costs. Debt included $250 million principal amount of 7.25% convertible notes due 2030, revenue bonds, equipment financing, and a related-party term loan. The term loan’s stated rate was 12.9% at year-end; $3.1 million of interest was paid in kind. The $150 million Sylebra revolving facility had no year-end borrowings.
Margins: The filing does not provide a meaningful commercial gross margin; sales were immaterial and the company had not reached significant continuous production. Operating costs rose 121% to $52.4 million, mainly due to Ironton depreciation, commissioning costs, employee costs, and facility rent. Research and development expense was $6.6 million; selling, general and administrative expense was $54.9 million.
Material changes versus FY2022
- Net loss increased $17.0 million, or 20%, while total operating costs and expenses rose 40%. Interest expense increased to $31.4 million from $2.3 million, reflecting new financing and the cessation of capitalized revenue-bond interest as Ironton assets entered service.
- A $33.8 million gain from changes in warrant fair value, compared with a $5.8 million expense in 2022, partially offset losses. The gain is valuation-driven and not equivalent to operating cash generation.
- Operating cash use increased $29.4 million. Capital spending remained substantial, although net investing cash use declined as investment purchases and capital expenditure payments fell from the prior year.
- Available unrestricted liquidity increased, but working capital declined. Much of the reported cash was restricted, limiting its availability for general operations.
- The company reduced its workforce by 22 employees in December 2023 as part of a cost and organizational review.
Outlook, risks, contingencies and unusual items
- Going concern: Management stated that year-end liquidity was insufficient to fund operations, commitments, and growth plans; the conditions raised substantial doubt about the company’s ability to continue as a going concern. Management considered the doubt alleviated by subsequent financing actions and expenditure adjustments. The auditor identified the going-concern analysis as a critical audit matter.
- Subsequent financing and bonds: On March 1, 2024, the Sylebra revolver was increased to $200 million and extended to September 30, 2025. On March 5, a subsidiary purchased 99% of the revenue bonds using $74.5 million of unrestricted cash and $184.6 million of restricted cash. Related amendments eliminated substantially all covenants and events of default under the bond documents. The purchase used significant liquidity; the filing does not provide a post-transaction unrestricted-liquidity balance in the supplied text.
- Project execution: Ironton’s commissioning, performance testing, product quality, permits, and ability to reach sustained output remain central risks. The bond purchase amendments eliminated the previous bond milestones, including production targets, but do not resolve the underlying operational challenges.
- Expansion and funding: Management expects to seek additional debt or equity for Augusta and other facilities. It disclosed approximately $53.8 million of Augusta commitments, $7.8 million for future facility and Feed PreP commitments, up to $12.5 million to complete the Ironton investment, and at least $38.0 million of interest payments, in addition to ongoing costs.
- Legal matters: Securities class actions and related derivative litigation remain unresolved; the company could not estimate potential losses. An Ironton contractor sought approximately $17 million in arbitration and a related lien action; PureCycle asserted counterclaims and could not estimate a potential loss.
- Accounting and controls: The company disclosed an immaterial correction to 2023 interim depreciation, increasing property and equipment and reducing depreciation expense by amounts that accumulated to $4.8 million through the nine months ended September 30, 2023. Management and the auditor reported effective internal control over financial reporting at year-end; prior material weaknesses were described as remediated.
- Other material risks include feedstock availability and cost, customer acceptance and pricing, technology scale-up, food-contact regulatory approvals, dependence on P&G’s license, high debt and financing costs, dilution, and facility safety and supply-chain disruptions.
Most important facts for investors to verify
- Current Ironton production rates, uptime, product specifications, independent certification status, and whether commercial sales have become material.
- Post-March 2024 cash availability after the bond purchase, restricted-fund releases, and any subsequent borrowing or bond re-marketing.
- Updated funding plan, construction schedule, and committed financing for Augusta and planned Feed PreP and international facilities.
- Debt balances, interest and principal obligations, related-party financing terms, and potential dilution from convertible notes, warrants, and equity issuance.
- Status and potential financial exposure of the securities litigation, derivative cases, and contractor arbitration.
- Scope of FDA clearances for intended feedstock and applications, and progress on additional regulatory submissions.